Spotlighting Angelini Pharma’s Focus on Brain Health: Novel Technologies & Modalities as Drivers of CNS Innovation
2:30 pm - Wednesday 9th December 2026
- Exploring how to leverage novel modalities to target epilepsy, neurodevelopmental disorders, depression, neuromuscular diseases and more
- Referencing Angelini’s ASO-centered partnership with Sovargen
- Discussing novel formulation approaches including LNPs for enhanced CNS targeting
